Navidea Receives $1.1M PDUFA Filing Fee Refund For Award Of Orphan Drug Status; Platinum Partners Reaffirms Commitment To Line Of Credit
November 11, 2014 at 07:30 AM EST
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) today announced it has received a $1.1 million refund of the previously paid ...